- Home
- MVST vs FENC Comparison
MVST vs FENC Comparison
Compare MVST & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- FENC
- Stock Information
- Founded
- MVST 2006
- FENC 1996
- Country
- MVST United States
- FENC United States
- Employees
- MVST N/A
- FENC N/A
- Industry
- MVST Industrial Machinery/Components
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVST Miscellaneous
- FENC Health Care
- Exchange
- MVST Nasdaq
- FENC Nasdaq
- Market Cap
- MVST 182.8M
- FENC 156.9M
- IPO Year
- MVST N/A
- FENC 2001
- Fundamental
- Price
- MVST $2.14
- FENC $5.74
- Analyst Decision
- MVST Buy
- FENC Strong Buy
- Analyst Count
- MVST 3
- FENC 2
- Target Price
- MVST $3.33
- FENC $14.00
- AVG Volume (30 Days)
- MVST 20.4M
- FENC 68.3K
- Earning Date
- MVST 11-12-2024
- FENC 11-07-2024
- Dividend Yield
- MVST N/A
- FENC N/A
- EPS Growth
- MVST N/A
- FENC N/A
- EPS
- MVST N/A
- FENC N/A
- Revenue
- MVST $370,989,000.00
- FENC $49,348,000.00
- Revenue This Year
- MVST $19.19
- FENC $170.43
- Revenue Next Year
- MVST $29.35
- FENC $6.70
- P/E Ratio
- MVST N/A
- FENC N/A
- Revenue Growth
- MVST 39.03
- FENC 278.09
- 52 Week Low
- MVST $0.15
- FENC $3.96
- 52 Week High
- MVST $2.87
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- MVST 56.17
- FENC 46.75
- Support Level
- MVST $1.97
- FENC $5.47
- Resistance Level
- MVST $2.30
- FENC $6.19
- Average True Range (ATR)
- MVST 0.36
- FENC 0.25
- MACD
- MVST -0.06
- FENC -0.09
- Stochastic Oscillator
- MVST 30.48
- FENC 24.77
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.